Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 3/20 | 0.55 |
| ▸ | FPR2 | P25090 | 1/20 | 0.54 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.53 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.53 |
| ▸ | ITGAL | P20701 | 4/20 | 0.53 |
| ▸ | NMBR | P28336 | 2/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ECE1 | P42892 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350138 | 1.00 | ALOX15 (0.56) | ALOX15ACEFPR2ITGB2ICAM1 | |
| SCHEMBL29417397 | 1.00 | ALOX15 (0.56) | ALOX15ACEFPR2ITGB2ICAM1 | |
| SCHEMBL29350130 | 1.00 | ALOX15 (0.56) | ALOX15ACEFPR2ITGB2ICAM1 | |
| SCHEMBL119594 | 1.00 | ALOX15 (0.56) | ALOX15ACEFPR2ITGB2ICAM1 | |
| SCHEMBL119372 | 1.00 | ALOX15 (0.56) | ALOX15ACEFPR2ITGB2ICAM1 | |
| Water SCHEMBL6022940 | 0.99 | ALOX15 (0.55) | ALOX15ACEFPR2ITGB2ICAM1 | |
| Fluoride SCHEMBL7154596 | 0.99 | ALOX15 (0.55) | ALOX15ACEFPR2ITGB2ICAM1 | |
| SCHEMBL29903356 | 0.93 | NMBR (0.55) | ACENMBRECE1 | |
| SCHEMBL30310986 | 0.93 | ACE (0.53) | ACEECE1 | |
| SCHEMBL29903302 | 0.93 | NMBR (0.55) | ACENMBRECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242572-A1 | a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGXI NORMAL UNIVERSITY (CN) | 2023-08-03 | — | — | US | claimed |
| CN-116075499-A | Novel dephosphorylated galectin derivatives with prodrug properties | 指南针探路者有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-102775471-B | Method for synthesizing cholecystokinin octapeptide by combining solid phase method and liquid phase method | GL BIOCHEM SHANGHAI CO LTD | 2013-10-30 | — | — | CN | claimed |
| CN-102775471-A | Method for synthesizing cholecystokinin octapeptide by combining solid phase method and liquid phase method | GL BIOCHEM SHANGHAI CO LTD | 2012-11-14 | — | — | CN | claimed |
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20240174714-A1 | TREATMENT OF SKIN DISORDERS | BACOBA AG (CH) | 2024-05-30 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| CN-111655758-B | Nucleic acid delivery polymers | 国立大学法人东京大学 | 2024-03-22 | — | — | CN | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | MIHKAL GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230242572-A1 | a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGXI NORMAL UNIVERSITY (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20080019993-A1 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2008-01-24 | — | — | US | disclosed |
| US-20080019993-A1 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2008-01-24 | — | — | US | disclosed |
| CN-100358584-C | Novel compositions magnetic particles covered with gem-bisphosphonate derivatives | GUERBET SA (FR) | 2008-01-02 | — | — | CN | disclosed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| CN-1744920-A | Novel magnetic particle compositions covered with gem-bisphosphonate derivatives | GUERBET SA (FR) | 2006-03-08 | — | — | CN | disclosed |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | MERCK SERONO SA (CH) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ALOX15 3621/4885ACE 621/4885FPR2 190/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | ALOX15 2821/4885ACE 282/4885FPR2 3112/4885 |
| US-20230242572-A1 | a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ACSL1, ACSL4, WEE1 | ALOX15 61/4885ACE 462/4885FPR2 3141/4885 |
| US-20080019993-A1 | Inhibition of tumour growth | STING1, VIP, MIF | ALOX15 325/4885ACE 1677/4885FPR2 312/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | ALOX15 3621/4885ACE 621/4885FPR2 190/4885 |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | HTR2A, HTR2C, HTR1D | ALOX15 2716/4885ACE 626/4885FPR2 879/4885 |
| US-20240174714-A1 | TREATMENT OF SKIN DISORDERS | HRH4, NR1H4, NR1H3 | ALOX15 175/4885ACE 4153/4885FPR2 698/4885 |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | OXTR, AVPR2, OPRL1 | ALOX15 1976/4885ACE 1265/4885FPR2 100/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ALOX15 3621/4885ACE 621/4885FPR2 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.